Benzodiazepine use and risk of stroke: A retrospective population-based cohort study
Version of Record online: 30 OCT 2013
© 2013 The Authors. Psychiatry and Clinical Neurosciences © 2013 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 68, Issue 4, pages 255–262, April 2014
How to Cite
Huang, W.-S., Muo, C.-H., Chang, S.-N., Chang, Y.-J., Tsai, C.-H. and Kao, C.-H. (2014), Benzodiazepine use and risk of stroke: A retrospective population-based cohort study. Psychiatry and Clinical Neurosciences, 68: 255–262. doi: 10.1111/pcn.12117
- Issue online: 4 APR 2014
- Version of Record online: 30 OCT 2013
- Manuscript Accepted: 18 SEP 2013
- Manuscript Revised: 12 SEP 2013
- Manuscript Received: 12 JUN 2013
- ‘Aim for the Top University Plan’ of the National Chiao Tung University and Ministry of Education, Taiwan, R.O.C.
- National Science Council. Grant Number: NSC 99–2314-B-039-016-MY2
- Taiwan Department of Health Clinical Trial and Research Center of Excellence. Grant Number: DOH102-TD-B-111-004
- Taiwan Department of Health Cancer Research Center of Excellence. Grant Number: DOH102-TD-C-111-005
- China Medical University Hospital. Grant Number: DMR-96-010
- cohort study;
The aim of this study was to investigate the possible association between benzodiazepine (BZD) use and risk of incident stroke by utilizing data from 2000 to 2003 from the National Health Insurance system of Taiwan.
Study subjects consisted of 38 671 patients with new BZD use and 38 663 people without BZD use who were frequency-matched for age, sex and baseline comorbidity with BZD users. All subjects had no history of stroke. Each study patient's case was followed until a new diagnosis of stroke was made or until the patient was censored by loss to follow up, death, or termination of insurance. The study lasted until the end of 2009. A Cox proportional hazards regression model was used to estimate the incidences and hazard ratios (HR) of stroke.
The HR of hemorrhagic stroke was significantly lower in the BZD group when compared with the non-BZD group. For patients aged 20–39 years, the HR of ischemic stroke was significantly higher in the BZD group when compared with the non-BZD group. Compared to the non-BZD group, patients with a lower annual dosage (<1 g) or duration (<30 days) of BZD use had a lower risk of stroke in the elder group (P < 0.0001) and patients with a higher annual dosage (≥ 4 g) or duration (≥ 95 days) of BZD use had a higher risk of stroke in all age groups (P < 0.0001).
Our findings may suggest neuroprotection under lower-dosage BZD use and neurotoxicity under higher-dosage BZD use.